Phillip Md Et Al Frost Purchases 533,300 Shares of OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 533,300 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was bought at an average cost of $1.27 per share, with a total value of $677,291.00. Following the transaction, the chief executive officer directly owned 214,966,448 shares of the company’s stock, valued at approximately $273,007,388.96. This trade represents a 0.25% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, November 19th, Phillip Md Et Al Frost bought 580,000 shares of OPKO Health stock. The shares were bought at an average price of $1.31 per share, for a total transaction of $759,800.00.
• On Friday, October 31st, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.42 per share, for a total transaction of $213,000.00.

OPKO Health Stock Up 2.3%

NASDAQ OPK opened at $1.31 on Thursday. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The business has a 50 day moving average price of $1.44 and a two-hundred day moving average price of $1.37. The stock has a market cap of $1.01 billion, a PE ratio of -5.24 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The business had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The business’s revenue for the quarter was down 12.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 earnings per share. As a group, sell-side analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on OPK shares. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 price objective (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Wall Street Zen raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $2.28.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently bought and sold shares of OPK. Brighton Jones LLC lifted its holdings in OPKO Health by 29.1% during the 2nd quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock worth $51,000 after buying an additional 8,775 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in OPKO Health by 4.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock worth $262,000 after purchasing an additional 8,954 shares during the last quarter. 360 Financial Inc. lifted its stake in OPKO Health by 12.0% during the second quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 9,500 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in OPKO Health by 11.2% in the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 13,912 shares during the period. Finally, Oak Thistle LLC bought a new stake in OPKO Health during the first quarter valued at $26,000. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.